Summary by Moomoo AI
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, has transitioned its accounting standards from International Financial Reporting Standards (IFRS) to U.S. Generally Accepted Accounting Principles (U.S. GAAP) as of January 1, 2024. This change was announced on June 17, 2024, and the company has re-issued its consolidated financial statements for the year ended December 31, 2023, under U.S. GAAP. These updated financial statements replace those included in the company's Annual Report on Form 20-F filed on April 4, 2024. NeuroSense Therapeutics, which focuses on developing treatments for neurodegenerative diseases, has not generated revenue to date and anticipates continued significant expenses and operating losses. The company reported net losses of $10.1 million for 2023 and $10.5 million for 2022, with an accumulated deficit of $26.1 million as of December...Show More
